CareDx, Inc.
Nov 2, 2017

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in three upcoming investor conferences.

Craig-Hallum Alpha Select Conference in New York City

29th Annual Piper Jaffray Healthcare Conference in New York City

Global Mizuho Investor Conference in New York City

Live audio webcasts of the Craig-Hallum Alpha Select Conference and the 29th Annual Piper Jaffray Healthcare Conference will be available online from the investor relations section of the CareDx website at http://investors.caredxinc.com/. The webcast replay of the presentation will be available approximately one hour following the conclusion of the live presentation and will be available on the Company's website for 90 days. Due to the one-on-one only format of the Global Mizuho Investor Conferences, no webcast will be available for this event. 

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.  

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com 

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com 

Source: CareDx, Inc.

News Provided by Acquire Media